1-3 of 3
Torsten Holm Nielsen
Close
Sort by
Journal Articles

Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma

Clinical Trials & Observations
Sarit E. Assouline, Torsten Holm Nielsen, Stephen Yu, Miguel Alcaide, Lauren Chong, David MacDonald, Axel Tosikyan, Vishal Kukreti, Abbas Kezouh, Tina Petrogiannis-Haliotis, Marco Albuquerque, Daniel Fornika, Sepideh Alamouti, Remi Froment, Celia M. T. Greenwood, Kathleen Klein Oros, Errol Camglioglu, Ayushi Sharma, Rosa Christodoulopoulos, Caroline Rousseau, Nathalie Johnson, Michael Crump, Ryan D. Morin, Koren K. Mann
Journal: Blood
Blood (2016) 128 (2): 185–194.
https://doi.org/10.1182/blood-2016-02-699520
Published: 2016
Includes: Supplemental data
Journal Articles

A Randomized, Phase II Study with Biomarker Analysis of Panobinostat with or without Rituximab in Relapsed Diffuse Large B Cell Lymphoma

Sarit Assouline, Michael Crump, MD, Torsten Holm Nielsen, Miguel Alcaide, B. Sc., Ph. D., David Macdonald, MD FRCPC, Axel Tosikyan, Tina Haliotis, Celia Greenwood, Kathleen Klein Oros, Ryan Morin, PhD, Nathalie Johnson, MD PhD, Koren Kathleen Mann, PhD
Journal: Blood
Blood (2015) 126 (23): 2719.
https://doi.org/10.1182/blood.V126.23.2719.2719
Published: 2015
Journal Articles

Targeting EVI1-Overexpressing AML with Darinaparsin

Koren K Mann, PhD, Nathalie Johnson, MD, Torsten Holm Nielsen, MD, Nicolas Garnier, MSc, Stanley Kwan, Eftihia Cocolakis, PhD, Josee Hebert, MD, Robert Morgan, MSc, Wilson H. Miller, Jr., MD, PhD
Journal: Blood
Blood (2011) 118 (21): 4269.
https://doi.org/10.1182/blood.V118.21.4269.4269
Published: 2011